Kirk Jacobson, MD
Internal Medicine · Eugene, ORNPI 1093707366
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 16.4% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$967
- Abbott$898
- Exact Sciences$588
- AstraZeneca$470
- Amgen$430
- Mannkind Corporation$211
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,865100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 76 | $967 |
| Abbott | 45 | $898 |
| Exact Sciences | 26 | $588 |
| AstraZeneca | 14 | $470 |
| Amgen | 34 | $430 |
| Mannkind Corporation | 13 | $211 |
| Boehringer Ingelheim | 8 | $180 |
| Lilly USA, LLC | 10 | $163 |
| Nestle Healthcare Nutrition Inc. | 8 | $160 |
| Terumo Medical Corporation | 1 | $136 |
| Nalu Medical, Inc. | 2 | $135 |
| Stryker | 1 | $134 |
| AbbVie(2 entities) | 6 | $132 |
| Sanofi-aventis U.S. LLC | 8 | $131 |
| Aimmune Therapeutics, Inc. | 7 | $125 |
| Dexcom, Inc. | 5 | $123 |
| Johnson & Johnson | 6 | $119 |
| Kowa Pharmaceuticals America, Inc. | 8 | $119 |
| Amarin Pharma, Inc. | 7 | $118 |
| Novo Nordisk | 6 | $106 |
| GSK | 4 | $72 |
| Edwards Lifesciences | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Bristol Myers Squibb | 2 | $37 |
| Medtronic | 1 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $27 |
| Eisai Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Blueprint Medicines Corporation | 1 | $19 |
| Novartis | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HydroPearl$136
- MAKO$134
- BREZTRI$130
- AIRSUPRA$130
- FARXIGA$130
- Nalu Neurostimulation System$106
How this compares
$5,886 in reported general payments places this provider in the 95th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 422 | $528,197 |
| OzempicSemaglutide | 212 | $272,106 |
| ZenpepLipase/Protease/Amylase | 42 | $127,139 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 81 | $66,880 |
| XareltoRivaroxaban | 61 | $65,128 |
| FarxigaDapagliflozin Propanediol | 58 | $63,192 |
| JardianceEmpagliflozin | 41 | $47,885 |
| TrulicityDulaglutide | 30 | $44,634 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $40,587 |
| EntrestoSacubitril/Valsartan | 28 | $35,276 |
| Repatha SureclickEvolocumab | 52 | $29,852 |
| MyrbetriqMirabegron | 34 | $29,590 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 178 | $26,525 |
| LinzessLinaclotide | 26 | $25,187 |
| SavellaMilnacipran Hcl | 22 | $22,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $967 | $537,432456 claims |
| Novo NordiskOzempic | $106 | $272,106212 claims |
| Aimmune Therapeutics, Inc.Zenpep | $125 | $127,13942 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $470 | $71,74669 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $163 | $68,73361 claims |
| Johnson & JohnsonXarelto | $119 | $65,12861 claims |
| Boehringer IngelheimJardiance | $180 | $47,88541 claims |
| AbbVieLinzess, Savella | $132 | $47,54748 claims |
| NovartisEntresto | $19 | $35,27628 claims |
| Astellas Pharma US IncMyrbetriq | $14 | $29,59034 claims |
| GSKTrelegy Ellipta | $72 | $7,91912 claims |
| Sanofi-aventis U.S. LLCLantus | $131 | $7,50832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,363 internal medicine providers in Oregon.
Other internal medicine in Eugene
- Marc UemuraEugene$20K
- Shehzad JinnahEugene$4K
- Chad PfeferBeaverton$639K
- Pranav ChandrashekarPortland$81K
- Jonathan EdmistonBend$68K
- Jessica CastlePortland$66K
- Ellen Schiaffino PurvisGresham$66K
- Steven ShawWhite City$58K
- Stephen SpurgeonPortland$42K
- Jane BabiarzPortland$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.